Influenza Therapeutics Market- Size, Share, Outlook,
and Opportunity Analysis, 2018 – 2026
Influenza is a condition that causes contagious illness. It is characterized by sudden onset of
fever, headache, sore throat, non-productive cough, and rhinitis. Usually infection lasts for
about a week. Over the course of a flu season, different types and subtypes of influenza can
cause illness in humans. There are four types of influenza virus such as A, B, C, and D.
Influenza A and B virus causes most of the illness in humans. Prolonged influenza infections
can cause severe complications such as pneumonia, bronchitis, acute respiratory distress,
secondary bacterial infections, and cardiovascular complications. To control the illness caused by
influenza virus, influenza antiviral prescription drugs can be used.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2443
Influenza Therapeutics Market: Drivers
New drug approvals for the treatment of influenza is expected to drive the influenza
therapeutics market growth. For instance, in October 2018, Roche announced that the U.S.
Food and Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the
treatment of acute, uncomplicated influenza or flu, in people 12 years of age and older.
Increasing number of clinical pipeline studies is expected to boost the influenza therapeutics
market growth during the forecast period. For instance, in January 2018, Romark Laboratories
L.C. initiated the phase 3 clinical trial for Nitazoxanide to evaluate its efficacy and safety in the
treatment of uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and broad-
spectrum antiviral drug, used in the treatment of intestinal parasitic infections caused by
Cryptosporidium parvam and Giardia lamblia. This study is expected to be completed in April
2019.
Influenza Therapeutics Market: Restraints
Influenza vaccines have several limitations including relatively long production times, limited
vaccine capacity, moderate efficacy in certain people, and lack of cross-reactivity, which is